Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity

類似資料

• Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
  著者:: Ting Hu, 等
  出版事項: (2020-11-01)
• In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand‐1 inhibitor in anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
  著者:: Du, Ping, 等
  出版事項: (2020)
• Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
  著者:: Sun, Yongkun, 等
  出版事項: (2016)
• Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
  著者:: Ren, Biyong, 等
  出版事項: (2021)
• Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
  著者:: Shi, Jingzhen, 等
  出版事項: (2020)